IL25 and neoplasm: Injection of recombinant IL‐25 every other day produced significant anti‐tumor activity, while combining IL‐25 with chemotherapeutic or immunotherapeutic agents showed greater antitumor efficacy in human tumor xenograft models in mice compared to each agent administered alone.